Interferon beta-1a vs. glatiramer acetate: changes of innate
immunity in a group of women with multiple sclerosis

J 2023

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

PETERKA, Marek; Martin VALIS; Ondrej SOUCEK; Jan KREJSEK; Lukas SOBISEK et. al.

Basic information

Original name

Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis

Authors

PETERKA, Marek (203 Czech Republic); Martin VALIS (203 Czech Republic); Ondrej SOUCEK (203 Czech Republic); Jan KREJSEK (203 Czech Republic); Lukas SOBISEK (203 Czech Republic); Ilona SEJKOROVA (203 Czech Republic); Blanka KLIMOVA (203 Czech Republic); Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution); Zbysek PAVELEK (203 Czech Republic) and Michal NOVOTNY (203 Czech Republic)

Edition

EUROPEAN NEUROLOGY, BASEL, KARGER, 2023, 0014-3022

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30210 Clinical neurology

Country of publisher

Switzerland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 2.100

RIV identification code

RIV/00216224:14110/23:00133490

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.1159/000532022

UT WoS

001036985900001

EID Scopus

2-s2.0-85176495640

Keywords in English

Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate

Abstract

In the original language

Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.

Cite

PETERKA, Marek; Martin VALIS; Ondrej SOUCEK; Jan KREJSEK; Lukas SOBISEK; Ilona SEJKOROVA; Blanka KLIMOVA; Pavel ŠTOURAČ; Zbysek PAVELEK and Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. EUROPEAN NEUROLOGY. BASEL: KARGER, 2023, vol. 86, No 5, p. 334-340, 14 pp. ISSN 0014-3022. Available from: https://doi.org/10.1159/000532022.

@article{2371617,
   author = {Peterka, Marek and Valis, Martin and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukas and Sejkorova, Ilona and Klimova, Blanka and Štourač, Pavel and Pavelek, Zbysek and Novotny, Michal},
   article_location = {BASEL},
   article_number = {5},
   doi = {https://doi.org/10.1159/000532022},
   keywords = {Multiple Sclerosis; Interferon Beta-1a; Glatiramer Acetate},
   language = {eng},
   issn = {0014-3022},
   journal = {EUROPEAN NEUROLOGY},
   title = {Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis},
   url = {https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate},
   volume = {86},
   year = {2023}
}

TY  - JOUR
ID  - 2371617
AU  - Peterka, Marek - Valis, Martin - Soucek, Ondrej - Krejsek, Jan - Sobisek, Lukas - Sejkorova, Ilona - Klimova, Blanka - Štourač, Pavel - Pavelek, Zbysek - Novotny, Michal
PY  - 2023
TI  - Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis
JF  - EUROPEAN NEUROLOGY
VL  - 86
IS  - 5
SP  - 334-340
EP  - 334-340
PB  - KARGER
SN  - 00143022
KW  - Multiple Sclerosis
KW  - Interferon Beta-1a
KW  - Glatiramer Acetate
UR  - https://karger.com/ene/article/86/5/334/860198/Interferon-Beta-1a-versus-Glatiramer-Acetate
N2  - Introduction: Multiple sclerosis is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to the axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. Methods: Sixty Caucasian female patients with relapsing-remitting multiple sclerosis undergo blood sample testing for 15 blood parameters at baseline, 1M, 3M and 6M after treatment by GA or IFN (started as their first line DMD). Results: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. Conclusion: Innate immunity has long been neglected in MS immunopathology. The findings of this study show that innate immunity cells, especially monocytes may contribute significantly to MS immunopathology.
ER  -

PETERKA, Marek; Martin VALIS; Ondrej SOUCEK; Jan KREJSEK; Lukas SOBISEK; Ilona SEJKOROVA; Blanka KLIMOVA; Pavel ŠTOURAČ; Zbysek PAVELEK and Michal NOVOTNY. Interferon beta-1a vs. glatiramer acetate: changes of innate immunity in a group of women with multiple sclerosis. \textit{EUROPEAN NEUROLOGY}. BASEL: KARGER, 2023, vol.~86, No~5, p.~334-340, 14 pp. ISSN~0014-3022. Available from: https://doi.org/10.1159/000532022.

Přehled o publikaci